NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42

Beta-amyloid (Abeta) peptides that accumulate in Alzheimer disease are generated from the beta-amyloid precursor protein (betaAPP) by cleavages by beta-secretase BACE1 and by presenilin-dependent gamma-secretase activities. Very few data document a putative cross-talk between these proteases and the regulatory mechanisms underlying such interaction. We show that presenilin deficiency lowers BACE1 maturation and affects both BACE1 activity and promoter transactivation. The specific gamma-secretase inhibitor DFK167 triggers the decrease of BACE1 activity in wild-type but not in presenilin-deficient fibroblasts. This decrease is also elicited by catalytically inactive gamma-secretase. The overexpression of APP intracellular domain (AICD), the gamma/epsilon-secretase-derived C-terminal product of beta-amyloid precursor protein, does not modulate BACE1 activity or promoter transactivation in fibroblasts and does not alter BACE1 expression in AICD transgenic brains of mice. A DFK167-sensitive increase of BACE1 activity is observed in cells overexpressing APPepsilon (the N-terminal product of betaAPP generated by epsilon-secretase cleavage harboring the Abeta domain but lacking the AICD sequence), suggesting that the production of Abeta could account for the modulation of BACE1. Accordingly, we show that HEK293 cells overexpressing wild-type betaAPP exhibit a DFK167-sensitive increase in BACE1 promoter transactivation that is increased by the Abeta-potentiating Swedish mutation. This effect was mimicked by exogenous application of Abeta42 but not Abeta40 or by transient transfection of cDNA encoding Abeta42 sequence. The IkappaB kinase inhibitor BMS345541 prevents Abeta-induced BACE1 promoter transactivation suggesting that NFkappaB could mediate this Abeta-associated phenotype. Accordingly, the overexpression of wild-type or Swedish mutated betaAPP does not modify the transactivation of BACE1 promoter constructs lacking NFkappaB-responsive element. Furthermore, APP/beta-amyloid precursor protein-like protein deficiency does not affect BACE1 activity and expression. Overall, these data suggest that physiological levels of endogenous Abeta are not sufficient per se to modulate BACE1 promoter transactivation but that exacerbated Abeta production linked to wild-type or Swedish mutated betaAPP overexpression modulates BACE1 promoter transactivation and activity via an NFkappaB-dependent pathway.     

细胞动粒蛋白Hec1启动子的结构及功能分析

细胞的分裂是一个严格调控,高度有序的过程.为了将复制后的染色体均匀、准确地传递给两个子细胞,细胞在分裂中后期受到纺锤体检验点的严格监控.Hec1定位于动粒,是纺锤体检验点调控的关键蛋白之一,它通过螺旋 螺旋结构域与其他动粒蛋白相互作用调节姐妹染色体的精确分离.为研究Hec1转录水平的调控机理,采用BLAST工具,从GenBank 中搜索到了人Hec1基因上游的序列,并利用在线工具http://mbs.cbrc.jp/research/db/TFSEARCH.html提供的转录因子结合位点搜索引擎,对其5′启动子调节区段进行了分析.分析结果表明：在Hec1基因上游-200～-1序列内,存在E2F、ATF4和cAMP应答元件结合蛋白（CREB）等转录因子调控元件.在结构分析的基础上,提取HeLa细胞基因组DNA,用PCR方法克隆了Hec1基因启动子,并构建了多个含启动子不同区段的pGL3荧光素酶报告基因表达质粒.瞬时转染HeLa细胞后的结果表明,-70～－63以及－155～－144之间的启动子区对维持荧光素酶活性最为关键.凝胶迁移实验证明,这两个区段分别能够和转录因子CREB以及ATF4结合.随后,采用野生型的以及含有133位磷酸化位点突变的CREB转染HeLa细胞,通过荧光定量PCR实验发现,Hec1的表达水平分别出现明显上升和下降.该结果表明,Hec1表达的调控是通过CREB的活化来完成的.